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PCSK9: Proprotein convertase subtilisin/kexin type 9 
SAMS Statin-associated muscle symptoms 
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1. Introduction 
The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the regulation of the 
LDL-receptor and plasma cholesterol was identified in 20031. This seminal discovery led to 
the rapid exploitation of PCSK9 as a drug target. Fifteen years later, investigators have 
completed two large outcomes trials of monoclonal antibody inhibitors of PCSK9 (PCSK9Is). 
Evolocumab was evaluated in The Further Cardiovascular Outcomes Research with PCSK9 
Inhibition in Subjects with Elevated Risk (FOURIER)2, and alirocumab was tested in the 
Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment 
With Alirocumab (ODYSSEY Outcomes)3 trials (Table 1). Treatment of patients with these 
agents has been remarkably successful in achieving lower plasma concentrations of LDL-C 
than had ever previously been attainable with lipid lowering therapy. Therefore, in addition to 
the ‘headline’ event-rate reduction results of these trials, which will certainly inform clinical 
practice, scrutiny of the trial data can yield more general information about lipid-lowering 
therapy. This commentary will briefly discuss what we have learned from outcome trials of 
evolocumab and alirocumab, and what the future holds for these agents. 
 
2. What have we learned from PCSK9I outcomes trials, and how has practice 
changed? 
The addition of alirocumab and evolocumab to lipid-lowering therapy with statins (with or 
without ezetimbe), has enabled the effective management of patient groups for whom 
achievement and maintenance of lipid-targets were previously extremely difficult. In particular 
the very large reductions in LDL-C elicited by PCSK9 inhibitors has been used to manage 
patients with familial hypercholesterolaemia (FH). Using these agents, it has been possible to 
meet LDL-targets for most of this population, and additionally for some of them (even for 
93%) it is now possible to entirely replace LDL-C apheresis (or to reduce the frequency of 
procedures) using PCSK9 inhibitor therapy. In several European countries, FH patients are the 
only group for whom reimbursement for PCSK9 inhibitors is allowed (Figure 1). The 
availability of an effective therapeutic approach to FH has in fact led to a revival in interest in 
this condition4 in many countries in which knowledge of this condition (and other genetically 
based lipid disorders) was very poor. Hopefully this will lead to redoubled efforts to identify 
undiagnosed FH patients.  
Statin intolerance, in particular statin-associated muscle symptoms (SAMS) is an important 
cause of statin non-adherence, discontinuation and suboptimal lipid management 5,6. Inhibitors 
of PCSK9 have also prompted discussion on the definition of statin intolerance and its effective 
diagnosis7. Additionally these agents have shown promise in the effective management of 
plasma lipid concentrations in statin intolerant patients, for whom there was previously no 
effective therapy5-7. The GAUSS-3 trial found that in patients with confirmed statin-
intolerance, evolocumab was associated with a 53% reduction in LDL-C at 24 weeks. Muscle 
symptoms were reported in only 21% of evolocumab-treated patients8. Similarly, in the 
ODYSSEY-alternative trial, alirocumab reduced mean LDL-C by 45% at 24 weeks9. In both 
cases PCSK9 inhibition was superior to ezetimibe. The demonstration of the concept of 
effective lipid-lowering in statin intolerant patients has led to trials investigating alternative 
lipid-lowering therapies such as bempedoic acid and to look for the other alternative therapies 
that might reduce LDL-C in patients with high cardiovascular (CV) risk10,11.  
The extremely low plasma concentrations of LDL-C achieved by treatment with PCSK9 
inhibitors has renewed focus on residual (i.e. non-LDL-C–mediated) risk for cardiovascular 
disease (CVD). This is timely in light of the recent demonstrations of the importance of 
inflammatory risk factors for cardiovascular disease in the Canakinumab Antiinflammatory 
Thrombosis Outcome Study (CANTOS)12 and Reasons for Geographic and Racial Differences 
in Stroke (REGARDS) study13. Additionally, the importance of lipoprotein(a) (Lp(a)) in 
mediating CV risk has received renewed attention. It is worth mentioning that purely on the 
basis of data with PCSK9 inhibitors, physicians in many countries worldwide have started 
(re)measuring Lp(a). This highly atherogenic and pro-thrombotic lipoprotein is resistant to 
many lipid-lowering therapies14, but appears to be effectively reduced by PCSK9 inhibitors15. 
Importantly, FOURIER2 and ODYSSEY-Outcomes3 have demonstrated conclusively that 
additional lipid-lowering therapy can be very beneficial in reducing cardiac outcomes in 
patients already taking optimal statin therapy. Previously, the Improved Reduction of 
Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) had demonstrated a reduction 
of a composite endpoint when ezetimibe was added to statin therapy16, however ODYSSEY-
Outcomes additionally demonstrated an important reduction in all-cause mortality with 
alirocumab 3  
Furthermore, ODYSSEY-Outcomes3 and FOURIER2 have added further evidence to 
support the ‘lower is better for longer’ paradigm with respect to LDL-C. In alirocumab-treated 
patients mean LDL-C levels at 4 months, 12 months, and 48 months were 0.98 mmol/l (38 
mg/dl), 1.1 mmol/l (42 mg/dl), and 1.4 mmol/l (53 mg/dl), respectively with the composite 
primary outcome (death from coronary heart disease, nonfatal myocardial infarction, fatal or 
nonfatal ischemic stroke, or unstable angina requiring hospitalization) reduced by 15% 
(95%Cl: 0.78-0.93) (with absolute risk reduction [aRR] 2% - number needed to treat [NNT]: 
50]3 . Patients treated with evolocumab achieved mean LDL-C of 2.4 mmol/l (30 mg/dl) and 
this was associated with a 15% reduction (95%Cl: 0.79-0.92; aRR=2%, NNT=50) in the 
primary outcome (a composite of cardiovascular death, myocardial infarction, stroke, 
hospitalisation for unstable angina or coronary revascularisation)2. A secondary analysis of the 
data revealed that the benefits persisted at LDL-C levels <0.5 mmol/L (20 mg/dL)17. 
Importantly, these benefits do not appear to be associated with excessive adverse effects and 
reassuringly, the rigorously conducted Evaluating PCSK9 Binding Antibody Influence on 
Cognitive Health in High Cardiovascular Risk Subjects (EBBINGHAUS) study found no 
evidence of cognitive impairment over a median of 19 months of evolocumab therapy18. 
 
How should PCSKIs be used in high-risk patients?  
The high acquisition cost of PCSK9 inhibitors, and the fact that high-risk individuals have 
been included in clinical trials has led to a discussion about the most appropriate method to 
stratify risk in the secondary prevention of CVD. Risk stratification is essential in order to 
select the patients who are most likely to benefit from treatments, and consequently to improve 
the cost-effectiveness of these medicines in measures such as Quality Adjusted Life Years 
(QALYs) and other techniques used economic evaluations of medicines. Based on the previous 
analyses PCSK9 inhibitor therapy should be considered in all high-risk patient groups where 
the number needed to treat (NNT) is less than 3019. Using the available data and sub-analyses 
of PCSK9 trials such patient groups have been identified by the International Lipid Expert 
Panel (ILEP)20 (Table 2), however further development of risk stratification algorithms would 
be extremely beneficial in deciding whether to initiate therapy with statin monotherapy, or to 
use combination therapy with statins and ezetimibe or a PCSK9 inhibitor from the outset. A 
risk stratification tool has previously been developed to assist therapeutic decision-making with 
respect to the initiation of the thrombin receptor antagonist vorapaxar in patients with ischemic 
heart disease21. A similar scheme for decision making with respect to PCSK9 inhibitors would 
likely include clinical details in addition to baseline lipid levels19 and coronary artery calcium 
scores22,23 to enable optimal decision making with respect to initial treatment. Based on these 
analyses we should consider changes in risk stratification for secondary prevention patients 
and introducing the group of extremely high risk patients to finally give clear answers as to 
which patients should be treated with the highest statin doses (80 mg atorvastatin and 40 mg 
rosuvastatin instead of the recommended ranges of 40-80 and 20-40 mg for atorvastatin and 
rosuvastatin, respectively), which patients should initiate treatment with combination therapy, 
and which ones might benefit the most from new therapies20. Furthermore, recently published 
findings and ongoing studies may potentially expand the scope of PCSK9I therapy to include 
new patient groups including pregnancy, primary prevention and comorbidities such as chronic 
kidney disease, and diabetes 20,24. 
 
What does the future hold for PCSK9 inhibitors? 
Recently published data from ODYSSEY-Outcomes3 and FOURIER2 suggests that 
evolocumab and alirocumab are extremely effective in lowering atherogenic lipoproteins, and 
consequently in preventing major adverse CV events. Availability of PCSK9 inhibitors to 
patients is determined by local policies on reimbursement. Such policies vary widely between 
countries, with no availability still in some countries, or with the reimbursement only for 
limited group of patients with FH in others (Figure 1). Cost-benefit analyses are likely to move 
in favour of PCSK9 inhibitors because of recent price reductions in these agents. In October 
2018, Amgen announced that it was lowering the price of Repatha® (evolocumab) by, by 
approximately 60% from $14,000 to $5850 a year. This followed an announcement in May 
2018 that Regeneron and Sanofi, the manufacturers of Praluent® (alirocumab) would reduce 
the price of this agent for a large number of patients. Physician familiarity with, and use of 
PCSK9Is is likely to increase following the publication of the recent American College of 
Cardiology and American Heart Association (ACC/AHA) Guideline on the Management of 
Blood Cholesterol. The guideline makes a class IIa recommendation for patients with multiple 
CV risk factors following acute coronary syndromes (ACS); but surprisingly a class IIb 
recommendation for patients with FH 25. 
With excellent clinical trial results and improving affordability, PCSK9-inibitors are likely 
to be a rational choice of lipid-lowering therapy in an increasing number of very high and 
extremely high-risk patients. In parallel with the rapid clinical developments, PCSK9 has 
continued to be remarkably fruitful field of study for basic scientists. As an alternative to 
monoclonal antibody inhibitors to PCSK9, the ORION series of clinical trials have 
demonstrated safety and lipid-lowering efficacy of inclisiran, a small interfering RNA (siRNA) 
which targets the messenger RNA for PCSK926. Recent preclinical studies have shown 
promising results for an anti-PCSK9 antisense oligonucleotide, which reduces serum PCSK9 
in a rat model 27. 
The remarkably rapid progress from the identification of PCSK9 as a drug target to the 
development, clinical evaluation and regulatory approval of multiple PCSK9Is is almost unique 
in modern medicine. This success is clearly due to close collaboration between basic scientists 
and clinical researchers in high-quality translational research projects. It is hoped that 
continued collaborative research will lead to more cost-effective therapies so that the 
remarkable benefits of PCSK9 inhibition can be extended to as many patients as possible.  
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Figure 1. The information on reimbursement of PCSK9 inhibitors in Europe (status as of 1st 
Nov. 2018).  
 
 
Table 1: Comparison of FOURIER and ODYSSEY-Outcomes trials 
 
 FOURIER2 ODYSSEY-Outcomes3 
Characteristics of study and participants 
Publication year 2017 2018  
Trial design Randomised double-blind placebo-controlled trial Randomised double-blind placebo-controlled 
trial 
Drug regiments Evolocumab subcutaneously either 140mg every 2 
weeks or 420mg monthly 
Alirocumab (dose adjusted to meet LDL-C 
target of 25 to 50 mg/dl) 
Mean follow-up 2.2 years 2.8 years 
Number of participants 27,564 18.924 
Mean age of participants 62.5 ± 9.1 (evolocumab) 
62.5 ± 8.9 (placebo) 
58.5 ± 9.3 (alirocumab) 
58.6 ± 9.4 (placebo) 
% of male participants 75.4% evolocumab 
75.5% placebo 
74.7 (alirocumab) 
74.9 (placebo) 
Main inclusion criteria Age >40 <85 
Clinically relevant ASCVD 
Additional ‘high risk’ characteristics 
Fasting LDL-C ³ 70mg/dl or non-HDL-C ³ 
100mg/dl on optimal therapy 
Age >40 
Hospitalized with ACS 1-12 months before 
randomization 
LDL-C ³ 70 mg/dl 
Non HDL-C ³ 100mg/dl or apolipoprotein B 
³ 80 mg/dl. 
 
Background therapy High intensity statin (69.3%) 
Moderate intensity statin (30.4%) 
Low intensity/ no data (0.03%) 
Ezetimibe (5.3%) 
High intensity atorvastatin/rosuvastatin 
(88.9%) 
Low/ moderate intensity 
atorvastatin/rosuvastatin (8.5%) 
Other statin (0.25%) 
No Statin (2.4%) 
Ezetimibe (2.9%) 
Endpoints and Results 
Primary endpoint and hazard ratio Composite of cardiovascular death, myocardial 
infarction, stroke, hospitalisation for unstable angina 
or coronary revascularisation. HR (95%CI) v 
placebo 0.85 (0.79-0.92) 
Composite of death from coronary heart 
disease, nonfatal myocardial infarction, fatal 
or nonfatal ischemic stroke, or unstable 
angina requiring hospitalization. HR (95%CI) 
v placebo 0.85 (0.78-0.93) 
  
Table 2: Selected groups of patients that might benefit most from the use of PCSK9 inhibitors based on the most recent data summarized by the 
International Lipid Expert Panel (ILEP)20.   
 
Patient group Background 
therapy 
Biomarkers NNT 
Patients with early ACS (up to 1-12 months) Optimal 
treatment 
Persistent LDL≥100 mg/dl 29 
 
Patient with fresh ACS (up to 1-12 months) Optimal 
treatment 
Persistent LDL≥70 mg/dl + diabetes mellitus and/or baseline Lp(a)> 
60 mg/dl 
30 
 
Patients with very high cardiovascular risk 
(after ACS) 
Optimal 
treatment 
Persistent LDL≥70 mg/dl + diabetes and/or baseline CRP> 3 mg/dl <30 
 
Patient in the group of very high 
cardiovascular risk (after ACS) on  
Optimal 
treatment 
Persistent LDL≥70 mg/dl + with concomitant PAD 29 
 
Patients with very high cardiovascular risk 
(after ACS)  
Optimal 
treatment 
Persistent LDL≥70 mg/dl + ≥2 previous ACS and initially with 
diabetes / Lp(a)>60 mg/dl / CRP> 3 mg/l 
<30 
 
 Patients with very high cardiovascular risk 
(after ACS) 
Optimal 
treatment 
Persistent LDL≥70 mg/dl + with multivessel disease 29 
 
